These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 28840997)

  • 1. Highly Aggressive de novo Aleukemic Variant of Mast Cell Leukemia Without KIT D816V Mutation.
    Suh MC; Ham JY; Park TI; Moon JH; Suh JS
    Ann Lab Med; 2017 Nov; 37(6):547-549. PubMed ID: 28840997
    [No Abstract]   [Full Text] [Related]  

  • 2. Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.
    Noack F; Sotlar K; Notter M; Thiel E; Valent P; Horny HP
    Leuk Lymphoma; 2004 Nov; 45(11):2295-302. PubMed ID: 15512820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. De novo leukemic variant of mast cell leukemia with KIT D816V.
    Bang HI; Park R; Park ES; Choi IH; Kim KH; Shin JW; Choi TY; Han K; Won JH
    Ann Lab Med; 2015 Mar; 35(2):260-2. PubMed ID: 25729733
    [No Abstract]   [Full Text] [Related]  

  • 4. De novo mast cell leukemia without CD25 expression and KIT mutations: a rare case report in a 13-year-old child.
    Zheng Y; Nong L; Liang L; Wang W; Li T
    Diagn Pathol; 2018 Feb; 13(1):14. PubMed ID: 29458385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case of de novo aleukemic mast cell leukemia without c-KIT mutations in exons 8 and 17.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ; Lee JH
    Int J Lab Hematol; 2014 Aug; 36(4):e44-6. PubMed ID: 24034180
    [No Abstract]   [Full Text] [Related]  

  • 6. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
    Gleixner KV; Mayerhofer M; Aichberger KJ; Derdak S; Sonneck K; Böhm A; Gruze A; Samorapoompichit P; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
    Blood; 2006 Jan; 107(2):752-9. PubMed ID: 16189265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mastocytosis: state of the art.
    Horny HP; Sotlar K; Valent P
    Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis.
    Escribano L; Díaz-Agustín B; Bellas C; Navalón R; Nuñez R; Sperr WR; Schernthaner GH; Valent P; Orfao A
    Leuk Res; 2001 Jul; 25(7):563-70. PubMed ID: 11377681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mastocytosis and related disorders.
    Chiu A; Orazi A
    Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
    Georgin-Lavialle S; Lhermitte L; Suarez F; Yang Y; Letard S; Hanssens K; Feger F; Renand A; Brouze C; Canioni D; Asnafi V; Chandesris MO; Aouba A; Gineste P; Macintyre E; Mansfield CD; Moussy A; Lepelletier Y; Dubreuil P; Hermine O
    Eur J Haematol; 2012 Jul; 89(1):47-52. PubMed ID: 22324351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of centralized evaluation of bone marrow histology in systemic mastocytosis.
    Jawhar M; Schwaab J; Horny HP; Sotlar K; Naumann N; Fabarius A; Valent P; Cross NC; Hofmann WK; Metzgeroth G; Reiter A
    Eur J Clin Invest; 2016 May; 46(5):392-7. PubMed ID: 26914980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FIP1L1-PDGFRA fusion gene and the KIT D816V mutation are coexisting in a small subset of myeloid/lymphoid neoplasms with eosinophilia.
    Schmitt-Graeff AH; Erben P; Schwaab J; Vollmer-Kary B; Metzgeroth G; Sotlar K; Horny HP; Kreipe HH; Fisch P; Reiter A
    Blood; 2014 Jan; 123(4):595-7. PubMed ID: 24458279
    [No Abstract]   [Full Text] [Related]  

  • 14. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.
    Gotlib J; Berubé C; Growney JD; Chen CC; George TI; Williams C; Kajiguchi T; Ruan J; Lilleberg SL; Durocher JA; Lichy JH; Wang Y; Cohen PS; Arber DA; Heinrich MC; Neckers L; Galli SJ; Gilliland DG; Coutré SE
    Blood; 2005 Oct; 106(8):2865-70. PubMed ID: 15972446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the observation of atypical cells on blood smear to the diagnosis of mast cell leukemia: a case report in a 79 year old woman consulting for anemia.
    Decker J; Meyer S; Latger-Cannard V; Visanica S; Loppinet E; Lesesve JF; Bénet B
    Ann Biol Clin (Paris); 2017 Dec; 75(6):689-694. PubMed ID: 29043985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does the aberrant expression of CD2 and CD25 by skin mast cells truly correlate with systemic involvement in patients presenting with mastocytosis in the skin?
    Lange M; Żawrocki A; Nedoszytko B; Wasąg B; Niedoszytko M; Jassem E; Nowicki R; Żmijewski MA; Biernat W
    Int Arch Allergy Immunol; 2014; 165(2):104-10. PubMed ID: 25402852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mast cell leukemia with novel BRAF variant and concomitant atypical KIT variant.
    Chen T; Malysz J; Washburn E; Songdej N; Zhang Y; Bayerl M
    Cancer Genet; 2022 Aug; 266-267():33-36. PubMed ID: 35717863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
    Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
    Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KIT D816V- chronic myelomonocytic leukemia progressing to KIT D816V+ associated to mast cell leukemia responding to allogeneic hematopoietic cell transplantation.
    Prats-Martín C; Jiménez-Guerrero P; Morales-Camacho RM; Caballero-Velázquez T; Vargas MT; Pérez O; Montero I; Falantes J; Burillo-Sanz S; Carrillo E; Borrero JJ; Bernal R; Pérez-Simón JA
    Ann Hematol; 2018 Mar; 97(3):533-535. PubMed ID: 29151134
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.